On October 22nd, the National Cancer Centre Singapore (NCCS) hosted a Charity GALA Dinner with the theme "Celebrating the past, Building hope for the future." Leman Biotech, as a representative of emerging enterprises in cancer immunotherapy, was invited by NCCS. Dr. Dudu Tong, the R&D Director, attended the grand event on behalf of the company and received a cordial reception from prominent figures, including Mr. Heng Swee Keat, the Deputy Prime Minister of Singapore.
On the afternoon of October 23rd, upon the invitation of Prof. Soo Khee Chee, the founding director of NCCS (pictured third from the left), Dr. Tong, together with Dr. Shuhao Wen, the founder of XtalPi Technology, visited the NCCS building at the Singapore General Hospital. They gained insights into the development of NCCS, and Dr. Tong provided a detailed presentation on the research progress of Leman Biotech's Metabolically Enhanced Immunotherapy. The discussion included exploring potential collaboration opportunities to bring high-quality cancer immunotherapy products to more patients in need.
The National Cancer Centre Singapore (NCCS) is located in the Medical Sciences Cluster of the Singapore General Hospital and serves as a national center for cancer diagnosis, research, and treatment in Singapore. Established in 1993, it is an autonomous institution affiliated with the National Healthcare Group, Singapore's largest public healthcare group. NCCS is the largest cancer treatment center in Singapore, with an expert team capable of treating various types of cancers, providing comprehensive inpatient care for patients. NCCS focuses on the prevention and treatment of different cancers, including breast cancer, hepatobiliary and pancreatic cancers, and head and neck cancers. NCCS boasts the highest number of "internationally certified oncologists" in Singapore, with over 50% of cancer patients in Singapore choosing to receive treatment at this center.
